BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100:1949-1956. [PMID: 16128938 DOI: 10.1111/j.1572-0241.2005.41956.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Mizoguchi M, Nakatsuji M, Inoue H, Yamaguchi K, Sakamoto A, Wada K, Inui T. Novel oral formulation approach for poorly water-soluble drug using lipocalin-type prostaglandin D synthase. European Journal of Pharmaceutical Sciences 2015;74:77-85. [DOI: 10.1016/j.ejps.2015.04.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
2 Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8. [PMID: 16700898 DOI: 10.1111/j.1365-2036.2006.02943.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 159] [Article Influence: 12.2] [Reference Citation Analysis]
3 Mailhe M, Ricaboni D, Vitton V, Gonzalez JM, Bachar D, Dubourg G, Cadoret F, Robert C, Delerce J, Levasseur A, Fournier PE, Angelakis E, Lagier JC, Raoult D. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol 2018;18:157. [PMID: 30355340 DOI: 10.1186/s12866-018-1304-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
4 Devault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009;6:524-32. [DOI: 10.1038/nrgastro.2009.125] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
5 Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007;8:2701-2717. [PMID: 17956193 DOI: 10.1517/14656566.8.16.2701] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
6 Hunt RH, Tytgat GH, Malfertheiner P, Fock KM, Heading RC, Katelaris PH, McCarthy DM, McColl KE, Moss SF, Sachs G, Sontag SJ, Thomson AB, Modlin IM. Whistler summary: "the slow rate of rapid progress". J Clin Gastroenterol 2007;41:539-45. [PMID: 17577108 DOI: 10.1097/MCG.0b013e31803d0fd8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Krznaric Z, Ljubas Kelecic D, Rustemovic N, Vranesic Bender D, Ostojic R, Markos P, Scarpignato C. Pharmaceutical principles of acid inhibitors: unmet needs. Dig Dis 2011;29:469-75. [PMID: 22095012 DOI: 10.1159/000331515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Scarpignato C. New drugs to suppress acid secretion: current and future developments. Drug Discovery Today: Therapeutic Strategies 2007;4:155-63. [DOI: 10.1016/j.ddstr.2007.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Strickland M, Ehrlich LS, Watanabe S, Khan M, Strub MP, Luan CH, Powell MD, Leis J, Tjandra N, Carter CA. Tsg101 chaperone function revealed by HIV-1 assembly inhibitors. Nat Commun 2017;8:1391. [PMID: 29123089 DOI: 10.1038/s41467-017-01426-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
10 Yuan Y, Hunt RH. Evolving issues in the management of reflux disease?: . Current Opinion in Gastroenterology 2009;25:342-51. [DOI: 10.1097/mog.0b013e32832c1504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Mckeage K, Blick SKA, Croxtall JD, Lyseng-williamson KA, Keating GM. Esomeprazole: A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults. Drugs 2008;68:1571-607. [DOI: 10.2165/00003495-200868110-00009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
12 Soisuwan S, Teeranachaideekul V, Wongrakpanich A, Langguth P, Junyaprasert VB. Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals. European Journal of Pharmaceutics and Biopharmaceutics 2019;137:68-76. [DOI: 10.1016/j.ejpb.2019.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Kung Y, Hsu W, Wu M, Wang J, Liu C, Su Y, Kuo C, Kuo F, Wu D, Wang Y. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci 2017;62:3298-316. [DOI: 10.1007/s10620-017-4830-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
14 Hunt RH, Yuan Y, Yaghoobi M. GERD: New Strategies and New Failures. Journal of Clinical Gastroenterology 2007;41:S72-80. [DOI: 10.1097/mcg.0b013e31803238d6] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127. [PMID: 20727892 DOI: 10.1053/j.gastro.2010.08.023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
16 Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41 Suppl 2:S226-S242. [PMID: 17575528 DOI: 10.1097/mcg.0b013e31803233b7] [Cited by in Crossref: 93] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
17 Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010;25:2205-11. [PMID: 20499372 DOI: 10.1002/jbmr.108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
18 Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, Shin JG. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42:278-284. [PMID: 22022918 DOI: 10.1517/13543776.2013.741121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
19 Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6. [PMID: 18076214 DOI: 10.2165/00003088-200847010-00001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
20 Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther. 2010;31:648-657. [PMID: 20015104 DOI: 10.1111/j.1365-2036.2009.04219.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
21 Hunt R. Acid Suppression for Reflux Disease: “Off-the-Peg” or a Tailored Approach? Clinical Gastroenterology and Hepatology 2012;10:210-3. [DOI: 10.1016/j.cgh.2011.11.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Mizoguchi M, Nakatsuji M, Takano J, Ishibashi O, Wada K, Inui T. Development of pH-Independent Drug Release Formulation Using Lipocalin-Type Prostaglandin D Synthase. J Pharm Sci 2016;105:2735-42. [PMID: 26886322 DOI: 10.1016/S0022-3549(15)00176-8] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
23 Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29:928-937. [PMID: 19298580 DOI: 10.1111/j.1365-2036.2009.03984.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
24 Armstrong D, Sifrim D. New pharmacologic approaches in gastroesophageal reflux disease. Gastroenterol Clin North Am. 2010;39:393-418. [PMID: 20951909 DOI: 10.1016/j.gtc.2010.08.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
25 Eriksen EK, Holm H, Jensen E, Aaboe R, Devold TG, Jacobsen M, Vegarud GE. Different digestion of caprine whey proteins by human and porcine gastrointestinal enzymes. Br J Nutr 2010;104:374-81. [PMID: 20307348 DOI: 10.1017/S0007114510000577] [Cited by in Crossref: 50] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
26 Tipnis NA, Rhee P, Mittal RK. Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms. American Journal of Physiology-Gastrointestinal and Liver Physiology 2007;293:G469-74. [DOI: 10.1152/ajpgi.00019.2007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
27 Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? World J Gastrointest Pharmacol Ther 2011; 2(3): 17-26 [PMID: 21731913 DOI: 10.4292/wjgpt.v2.i3.17] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
28 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Boeckxstaens G. Emerging drugs for gastroesophageal reflux disease. Expert Opinion on Emerging Drugs 2009;14:481-91. [DOI: 10.1517/14728210903133807] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther 2006;23 Suppl 2:23-34. [PMID: 16700900 DOI: 10.1111/j.1365-2036.2006.02945.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
31 Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis. 2006;24:11-46. [PMID: 16699262 DOI: 10.1159/000091298] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
32 Wang YK, Hsu WH, Wang SS, Lu CY, Kuo FC, Su YC, Yang SF, Chen CY, Wu DC, Kuo CH. Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract 2013;2013:983653. [PMID: 23878534 DOI: 10.1155/2013/983653] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
33 Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Clin Exp Gastroenterol 2014;7:461-71. [PMID: 25525378 DOI: 10.2147/CEG.S67672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Biochem Pharmacol 2006;71:837-49. [PMID: 16405921 DOI: 10.1016/j.bcp.2005.11.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
35 Ghatak S, Reveiller M, Toia L, Ivanov AI, Zhou Z, Redmond EM, Godfrey TE, Peters JH. Bile Salts at Low pH Cause Dilation of Intercellular Spaces in In Vitro Stratified Primary Esophageal Cells, Possibly by Modulating Wnt Signaling. J Gastrointest Surg 2016;20:500-9. [PMID: 26715559 DOI: 10.1007/s11605-015-3062-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
36 Altan E, Blondeau K, Pauwels A, Farré R, Tack J. Evolving pharmacological approaches in gastroesophageal reflux disease. Expert Opin Emerg Drugs. 2012;17:347-359. [PMID: 22834684 DOI: 10.1517/14728214.2012.702753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
37 Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11:27-37. [PMID: 27840364 DOI: 10.5009/gnl15502] [Cited by in Crossref: 147] [Cited by in F6Publishing: 119] [Article Influence: 29.4] [Reference Citation Analysis]
38 Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005;22:10-9. [DOI: 10.1111/j.1365-2036.2005.02715.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
39 Ang TL, Fock KM. Nocturnal acid breakthrough: Clinical significance and management. J Gastroenterol Hepatol 2006;21:S125-8. [DOI: 10.1111/j.1440-1746.2006.04717.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
40 Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci 2008;65:264-81. [PMID: 17928953 DOI: 10.1007/s00018-007-7249-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
41 Shin JS, Lee JY, Cho KH, Park HL, Kukulka M, Wu JT, Kim DY, Park SH. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. Aliment Pharmacol Ther 2014;40:548-61. [PMID: 25041486 DOI: 10.1111/apt.12860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
42 Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534. [PMID: 19006606 DOI: 10.1007/s11894-008-0098-4] [Cited by in Crossref: 192] [Cited by in F6Publishing: 163] [Article Influence: 14.8] [Reference Citation Analysis]
43 Louw JA. Peptic ulcer disease. Curr Opin Gastroenterol 2006;22:607-11. [PMID: 17053437 DOI: 10.1097/01.mog.0000245532.12648.aa] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
44 Hunt RH, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, Shin JM, Lee E, Tang-Liu D, Sachs G. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28:187-99. [PMID: 18445141 DOI: 10.1111/j.1365-2036.2008.03725.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
45 Kukulka M, Nudurupati S, Perez MC. Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration. Clin Exp Gastroenterol 2017;10:47-56. [PMID: 28255251 DOI: 10.2147/CEG.S121129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
46 Sripathi S, Bojja RR, Karnati VR, Raju VVNKVP, Khunt MD. An Improved Synthesis of Antiulcerative Drug: Tenatoprazole. Org Process Res Dev 2009;13:804-6. [DOI: 10.1021/op800173u] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Soisuwan S, Teeranachaideekul V, Wongrakpanich A, Langguth P, Junyaprasert VB. In vitro performances and cellular uptake of clarithromycin nanocrystals produced by media milling technique. Powder Technology 2018;338:471-80. [DOI: 10.1016/j.powtec.2018.07.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
48 Thomson AB, Cohen P, Ficheux H, Fiorentini P, Domagala F, Homerin M, Taccoen A. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23:1179-1187. [PMID: 16611279 DOI: 10.1111/j.1365-2036.2006.02781.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
49 Galmiche JP, Zerbib F, des Varannes SB. Treatment of GORD: Three decades of progress and disappointments. United European Gastroenterol J 2013;1:140-50. [PMID: 24917952 DOI: 10.1177/2050640613484021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
50 Wang H, Wang AJ, Zhu X. Advances in drug therapy for gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2011; 19(16): 1711-1719 [DOI: 10.11569/wcjd.v19.i16.1711] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32:258-264. [PMID: 21429600 DOI: 10.1016/j.tips.2011.02.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
52 Armstrong D, Sifrim D. New pharmacologic approaches in gastroesophageal reflux disease. Thorac Surg Clin 2011;21:557-74. [PMID: 22040637 DOI: 10.1016/j.thorsurg.2011.09.005] [Reference Citation Analysis]